The World's First Single-Use, Fog-Free, Portable, High-Definition Laparoscopic Imaging System Provides Significant Clinical and Economic Benefits
FREMONT, CA: Xenocor Inc. declares a strategic investment by Barvest Ventures Inc., a subsidiary of the Trudell Medical Group, a global leader in respiratory care and medical device development. This investment enables Xenocor to increase production and meet the growing demand for the Xenoscope™, an FDA-approved, single-use, fog-free, portable, high-definition (HD) laparoscopic imaging system.
Additionally, George Baran, the Trudell Medical Group chairman, joins the Xenocor board of directors, bringing years of market insight and experience in product development, manufacturing, and global market distribution. Northgate Technologies Inc., a Trudell Medical Group member company that designs and manufactures urology and minimally invasive surgical equipment, collaborates closely with Xenocor to maximize the relationship's synergies.
“Innovation has been critical for delivering solutions that improve quality of life and create positive economic outcomes. This has been our mission since our inception in 1922,” says George Baran, Chairman of the Trudell Medical Group. “We feel our investment in Xenocor is a continuation of this tradition and see every reason for the Xenoscope to be successfully introduced into many markets around the world.”
The Xenoscope provides clinical and financial benefits that positively impact surgeons, staff, facilities, and patients. Technological innovations significantly improve image quality (HD and fog-free), eliminate cross-contamination, reduce arc-patient burn injuries, minimize technical complications and downtime in operating rooms. The compact, portable design is a single cord plug-and-play unit, enabling easy integration and multi-location use. There are no significant capital expenses or expensive long-term maintenance contracts, so Xenoscope is readily accessible to varying size markets.
"Not only is Trudell Medical Group a global leader in its product categories, but they also manufacture adjunct products that complement our current offerings. This strategic investment alliance is a win-win partnership, which leaves the door open to additional innovation,” says Evan Kelso, CEO of Xenocor. “We feel fortunate to have George Baran on the board and such a commanding ally as we move this product into broader availability.”
Trudell Medical Group, a family-owned company, was founded in 1922 and is headquartered in Ontario, Canada. Trudell Medical Group member companies specialize in developing, manufacturing, and distributing innovative medical devices, including the well-known valved holding chamber AeroChamber Plus® and the Northgate Technologies NEBULAE® I System, a high-flow laparoscopic insufflator. With distribution in over 100 countries, Trudell focuses on meeting patients' unmet needs and delivering solutions that improve quality of life.
Xenocor offers a suite of leading, fog-free, single-use endoscopes for minimally invasive surgery. This technology emerged from Utah's Center for Medical Innovation. The current product offerings are FDA-free, CE-marked, and patent-protected. Xenocor is a private corporation in Salt Lake City, UT.